Mycoplasma contamination can silently compromise cell culture performance, distort analytical readouts, and undermine the reliability of biologics development and manufacturing workflows. Because these wall-less microorganisms are difficult to detect by visual inspection and can persist in complex matrices, effective mycoplasma testing requires both scientific rigor and fit-for-purpose method design. BOC Sciences provides comprehensive mycoplasma testing services for cell cultures, cell banks, raw materials, in-process samples, biologic intermediates, and final products. Our team combines rapid molecular detection, classical culture-based confirmation, matrix suitability assessment, and contamination risk evaluation to help clients identify hidden contamination events, protect valuable materials, and support robust decision-making across research, process development, and quality control environments.
We use highly sensitive qPCR workflows to detect mycoplasma DNA in diverse sample matrices, providing a fast and practical solution for contamination screening throughout biologics and cell-based development programs.
For projects requiring viable organism recovery and orthogonal confirmation, we perform classical culture-based mycoplasma testing using carefully controlled enrichment and detection workflows.
Many biologic matrices contain inhibitory substances, antimicrobials, residual process chemicals, or high background nucleic acid loads. We design suitability studies to confirm that the selected assay performs reliably in your specific sample context.
When unexpected cell behavior, inconsistent potency, or unexplained process deviations suggest hidden contamination, BOC Sciences provides investigational testing support to help localize and characterize potential mycoplasma risks.
BOC Sciences provides scientifically designed mycoplasma testing workflows to protect cell cultures, biologic materials, and development timelines from silent contamination.
Our rapid molecular workflows use real-time PCR to detect mycoplasma nucleic acid with high sensitivity, enabling fast screening of cell culture supernatants, harvest samples, and biologic matrices where speed and confidence are both essential.
We apply extraction and pretreatment strategies tailored to sample complexity, improving nucleic acid recovery while minimizing matrix-associated inhibition from proteins, salts, surfactants, serum components, and process residues.
For viable organism detection and orthogonal confirmation, we deploy specialized enrichment media and culture workflows that improve the recovery of slow-growing or low-level mycoplasma contaminants from challenging sample types.
We incorporate inhibition checks and matrix suitability assessments into project planning to reduce the risk of false-negative outcomes and improve assay reliability in complex, process-relevant test articles.
Our analytical strategy supports side-by-side testing of upstream, in-process, and downstream samples, helping clients identify the probable origin and spread pattern of suspected mycoplasma contamination events.
Beyond issuing results, we help contextualize findings against cell performance, assay variability, and process history, supporting technically sound decisions on sample disposition, repeat testing, and contamination response.
BOC Sciences supports mycoplasma testing across a wide range of research, development, and manufacturing-relevant sample types. Whether you are screening an early-stage cell culture, investigating a suspicious production deviation, or evaluating biologic materials before critical downstream activities, we can design a testing strategy aligned with your sample characteristics and project goals.
Submit your sample background, matrix type, and testing objective. Our scientists will design a fit-for-purpose workflow for screening, confirmation, or contamination investigation.
We review your sample type, biological matrix, development stage, and contamination concerns to determine the most appropriate testing route, including rapid molecular detection, culture-based evaluation, or a combined orthogonal strategy.
Our team evaluates matrix interference risks and defines pretreatment, extraction, enrichment, or dilution approaches needed to preserve assay sensitivity and result integrity in your specific test article.
We perform the selected assays under controlled conditions, review analytical quality indicators, and interpret findings in the context of your material history, process background, and expected sample behavior.
You receive a clear, project-relevant report summarizing the testing approach, result interpretation, and recommended next actions, whether for routine screening, contamination investigation, or follow-up testing design.
Mycoplasma contamination often produces no visible turbidity and may remain undetected while gradually altering growth kinetics, metabolism, gene expression, and protein production. BOC Sciences addresses this risk through sensitive detection strategies designed for routine screening of cell cultures, cell banks, and process samples, helping clients identify contamination before it drives misleading experimental conclusions or expensive downstream setbacks.
Biologic samples can contain inhibitors that suppress nucleic acid amplification or reduce recovery efficiency. Our suitability-driven approach evaluates matrix effects early, then applies targeted pretreatment and extraction optimization to minimize interference and improve confidence in negative results, especially for protein-rich, serum-containing, or process-complex samples.
Different project stages require different analytical priorities. Early-stage research may emphasize rapid screening, while later process evaluation may require orthogonal confirmation and broader contamination mapping. We help clients align assay choice with program needs, integrating qPCR speed with culture-based depth when the sample context or decision impact calls for a more comprehensive strategy.
When mycoplasma appears repeatedly, the root cause may lie in raw materials, shared handling steps, seed stocks, or previously affected cultures. BOC Sciences supports structured contamination investigations by comparing multiple sample points across the workflow, helping clients narrow likely entry routes and make more informed corrective decisions.
Partner with BOC Sciences for scientifically grounded testing strategies that help safeguard cell lines, biologic materials, and manufacturing workflows from hidden mycoplasma risks.
We match the testing strategy to your sample type, project stage, and technical objective rather than forcing all projects into a single standard workflow.
Our platform supports both fast qPCR-based screening and deeper culture-based evaluation, enabling flexible decision support for research and manufacturing teams.
We understand that biologic and process samples are rarely simple. Our workflows are built to address inhibitory matrices and preserve confidence in result interpretation.
We do more than report a signal. Our scientists help interpret findings in relation to cell performance, assay behavior, and broader contamination risk across your workflow.
Client Needs: A biologics developer observed unstable growth behavior and inconsistent recombinant glycoprotein expression in a mammalian production platform derived from a long-maintained working cell bank.
Challenges: No visible turbidity or obvious bacterial contamination was present, and standard culture observation had not explained the gradual decline in process consistency.
Solution: BOC Sciences implemented a targeted qPCR mycoplasma screening plan covering the working bank, current expansion cultures, archived supernatants, and selected raw material inputs. We also incorporated matrix suitability controls to exclude amplification suppression, reviewed sampling points against the cell expansion history, and compared signal patterns across historical and current materials to support source differentiation.
Outcome: Low-level mycoplasma contamination was identified in the working bank-associated material but not in archived master-bank samples. The client was able to isolate the affected stage, preserve uncontaminated seed material, and rebuild the expansion workflow with improved confidence.
Client Needs: A partner developing a high-concentration monoclonal antibody intermediate required rapid mycoplasma screening before advancing multiple purification and conjugation-related studies.
Challenges: The protein-rich matrix and formulation components created a substantial risk of nucleic acid amplification inhibition, raising concern that a negative result could be misleading.
Solution: We performed a method suitability assessment using controlled spike-recovery design, then optimized pretreatment and extraction conditions to reduce inhibitory interference while maintaining analytical sensitivity. The final workflow combined molecular screening with technical review criteria tailored to the sample matrix, including internal control evaluation and result interpretation steps suitable for complex biologic intermediates.
Outcome: The optimized assay delivered clear, interpretable results and gave the client greater confidence in sample disposition decisions for downstream biologics development activities.
Client Needs: A project team producing a cell-derived therapeutic intermediate experienced recurring process inconsistency across separate upstream campaigns and suspected an intermittent contamination source.
Challenges: The contamination event was not uniformly present across all batches, making it difficult to determine whether the origin was a raw material, seed train step, handling practice, or equipment-related transfer point.
Solution: BOC Sciences designed a comparative testing map spanning incoming supplements, early-stage inoculation samples, intermediate culture points, and final harvest-associated material. Rapid qPCR screening was paired with targeted confirmatory evaluation and sample-stage comparison to identify the most plausible contamination entry window while avoiding unnecessary testing of unrelated process materials.
Outcome: The data narrowed the likely source to a restricted upstream handling segment linked to a specific material introduction step. This enabled the client to focus corrective measures efficiently and reduce recurrence risk in subsequent runs.
Mycoplasma testing is the detection of small, wall-less bacterial contaminants that can silently affect cell cultures, cell banks, biologics workflows, and other cell-based drug development materials. Because mycoplasma may not cause visible turbidity or obvious culture changes, routine testing helps protect data reliability, assay consistency, and downstream development decisions. BOC Sciences supports drug developers with mycoplasma testing services designed for cell culture quality assessment, process monitoring, and contamination risk management across research and development workflows.
Mycoplasma contamination is difficult to detect because these microorganisms are very small, lack a rigid cell wall, and may grow without producing the visual signs often associated with bacterial or fungal contamination. Infected cultures can continue to proliferate while showing altered metabolism, gene expression, growth behavior, or assay responses. This hidden impact makes targeted testing more reliable than visual inspection alone, especially when cell-based data influence candidate selection, comparability studies, or analytical development.
Common sample types for mycoplasma testing include cell culture supernatants, cell suspensions, master or working cell bank materials, process intermediates, and cell-derived development samples. The best sample depends on the culture system, testing objective, and where contamination risk is most relevant in the workflow. BOC Sciences can help clients select appropriate sampling points and testing strategies so that mycoplasma screening supports early research, assay development, cell line characterization, and biologics development without disrupting core project activities.
Cell cultures should be tested at meaningful checkpoints rather than only after visible problems appear. Common high-value moments include establishing or receiving a new cell line, before creating cell banks, after thawing important cultures, before critical experiments, during long-term passaging, and when unexplained assay variability occurs. For drug development teams, routine screening helps reduce the risk of repeating studies, misinterpreting biological activity, or advancing compromised materials into more resource-intensive development work.
If mycoplasma is detected, the first priority is to isolate affected cultures, review possible contamination sources, and decide whether the material should be discarded, replaced, or recovered based on its scientific value. Retesting and contamination-control review can help confirm findings and prevent recurrence. BOC Sciences can support clients with follow-up testing, method selection, contamination investigation, and broader microbial quality services, helping development teams make evidence-based decisions while protecting valuable cell-based assets.
BOC Sciences did not treat our project as a routine screen. Their team first examined the matrix risk, then recommended a more suitable workflow. That technical judgment made the result far more valuable for our cell bank decision-making.
— Dr. Helen R., Head of Cell Line Development
We were dealing with inconsistent upstream performance and needed more than a simple positive or negative answer. Their comparative testing strategy helped us narrow the likely contamination source and move forward with a much clearer action plan.
— Michael T., Senior Process Development Manager
Our biologic intermediate was a difficult matrix, and false negatives were a real concern. BOC Sciences carefully addressed inhibition and delivered results we could genuinely trust for internal development decisions.
— Dr. Anna K., Analytical Development Scientist
The report was not just technically sound, it was useful. The interpretation connected the data to our workflow, sample history, and next-step options, which made communication across our team much easier.
— James P., CMC Project Lead
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
